{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:11:38Z","timestamp":1782029498918,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ymgme.2016.02.006","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T20:22:33Z","timestamp":1455999753000},"page":"419-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies"],"prefix":"10.1016","volume":"117","author":[{"given":"Yong","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2016.02.006_bb0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.beem.2015.01.006","article-title":"The role of antibodies in enzyme treatments and therapeutic strategies","volume":"29","author":"Bigger","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0025","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10928-009-9132-x","article-title":"Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme\u00ae","volume":"36","author":"Bonate","year":"2009","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2016.02.006_bb0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1750-1172-6-55","article-title":"Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"de Ru","year":"2011","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0040","first-page":"2868","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J.Clin. Invest."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0045","first-page":"783","article-title":"The six-minute walk test","volume":"48","author":"Enright","year":"2003","journal-title":"Respir. Care"},{"key":"10.1016\/j.ymgme.2016.02.006_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","article-title":"A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I","volume":"96","author":"Giugliani","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0055","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"36","author":"Hendriksz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009354.pub2","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme\u00ae) for treating mucopolysaccharidosis type I","volume":"11","author":"Jameson","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0065","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2014.10.012","article-title":"Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy","volume":"114","author":"Langereis","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0080","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.biopsych.2005.04.032","article-title":"Vaccine pharmacotherapy for the treatment of cocaine dependence","volume":"58","author":"Martell","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ymgme.2016.02.006_bb0095","unstructured":"Neufeld EF. Enzyme replacement therapy\u2014a brief history. In: Mehta A, Beck M, Sunder-Plassmann G, editors., eds. Fabry Disease: Perspectives from 5Years of FOS. Oxford, England: Oxford PharmaGenesis; 2006."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13023-015-0255-4","article-title":"Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome","volume":"10","author":"Pal","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0105","series-title":"Pulmonary Function Testing in Children: Techniques and Standards","first-page":"100","author":"Polgar","year":"1971"},{"key":"10.1016\/j.ymgme.2016.02.006_bb0110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol. Gnet. Metab."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0120","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0125","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1128\/IAI.73.6.3598-3608.2005","article-title":"Human immune response to a plague vaccine comprising recombinant F1 and V antigens","volume":"73","author":"Williamson","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0130","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human \u03b1-l-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2016.02.006_bb0135","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysacchardiosis I and are younger than 5years: results of a multinational study of recombinant human \u03b1-l-iduronidase (laronidase)","volume":"120","author":"Wraith","year":"2007","journal-title":"Pediatrics"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921630018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921630018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T01:21:16Z","timestamp":1536974476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671921630018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S109671921630018X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.02.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}